Company profile
SCHRODINGER, INC.
NASDAQ:SDGRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SGR-1505 | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05544019 | phase1 | recruiting | 2023-04-10 | 2027-11-01 | Schrödinger, Inc. | Study of SGR-1505 in Mature B-Cell Neoplasms |
| NCT05961839 | phase1 | terminated | 2023-09-27 | 2025-08-14 | Schrödinger, Inc. | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| NCT06463340 | phase1 | recruiting | 2024-06-18 | 2026-10-31 | Schrödinger, Inc. | Study of SGR-3515 In Participants With Advanced Solid Tumors. |
FDA applications (0)
No records yet.